Recent News: Gain Peace of Mind with the Lentiviral Experts
The lentiviral vector market is rapidly growing, with projections showing it will reach $16.48 billion in 2025, up from $14.37 billion in 2024, driven by increased demand for gene delivery and the prevalence of chronic and genetic disorders1.
Technological advancements are enhancing vector reliability and scalability; platforms like LentiSure are expanding efficient production for cell-based immuno-oncology therapies, which assures higher quality and productivity for developers and manufacturers1.
Major progress in clinical applications includes regulatory approval for specialized therapies; for example, in July 2025, the European Commission approved a CAR-T therapy manufactured with lentiviral vectors by AGC Biologics, marking a significant advance in the use of lentiviral technology for cancer treatment3.
The lentiviral sector is bolstered by increased investment in biotechnology, breakthroughs in personalized medicine, and innovations in production methodologies, leading to its adoption in advanced therapies for rare diseases and expanded research and clinical trials1.
Sources:
1. https://www.openpr.com/news/4182441/key-factor-supporting-lentiviral-vector-market-development
3. https://www.agcbio.com/news/european-commission-approves-car-t-therapy-with-lentiviral-vectors-manufactured-by-agc-biologics